In-Hospital Mortality Rate and Predictors of 30-Day Readmission in Patients With Heart Failure Exacerbation and Atrial Fibrillation: A Cross-Sectional Study

Karthik Gangu, Aniesh Bobba, Harleen Kaur Chela, Sindhu Avula, Sanket Basida, and Neha Yadav

Background and Objectives: Heart failure (HF) and atrial fibrillation (AF) are considered new cardiovascular epidemics of the last decade. Recent national trends show an uptrend in HF hospitalizations. We aimed to identify the 30-day readmission rate, causes, and impact on healthcare utilization in HF exacerbation with a history of AF.

Methods: We utilized 2018 Nationwide readmission data and included patients aged ≥18 years with International Classification of Diseases, Tenth Revision, Clinical Modification code indicating HF exacerbation and AF were included in the study. Primary outcome is 30-day readmission rates. Secondary outcomes were mortality rates, common causes of readmission, and healthcare utilization. Independent predictors for readmission were identified using cox regression analysis.

Results: The total number of admissions in our study was 48,250. The mean age was 77.8 years (standard deviation, 12.1), and 47.74% were females. The 30-day readmission rate was 16.72%. The mortality rate at index admission and readmission was 7.28% and 8.12%, respectively. The most common cause of readmission was the hypertensive heart and kidney disease with HF. The independent predictors of readmission were low socio-economic class, Medicaid, Charlson comorbidities score. The financial burden on healthcare for all the readmission was $461 million for the year 2018.

Conclusions: The 30-day readmission rate was 16.72%. The mortality rate increased from 7.28% to 8.12% with readmission. The financial burden for readmission during that year was $461 million. Future studies directed with interventions to prevents readmissions are warranted.

Keywords: Thirty-day readmission; Diastolic heart failure; Systolic heart failure; Atrial fibrillation
INTRODUCTION

Data from Framingham Heart Study participants showed that atrial fibrillation (AF) occurs in more than half of individuals with heart failure (HF), and HF occurs in more than one-third of individuals with AF. It is estimated that around 6.2 million people in the US have HF. Approximately 13.4% of deaths in 2018 have HF mentioned in the death certificate. HF exacerbation poses a major financial burden on society, and it was estimated to cost around $30.7 billion in 2012.

AF and HF share common risk factors. Prevalence of AF has been reported to range from 27% to 65% in HF patients with increasing rates in HF with preserved ejection fraction (HFpEF). AF is associated with increased long-term mortality and morbidity. Data from the Swedish Heart Failure registry showed AF increased hazards of HF hospitalizations regardless of the ejection fraction over 12-year period, and the European Society of Cardiology-Heart Failure long-term registry showed an increased risk of hospitalizations in HF with mildly reduced ejection fraction and HFpEF. Data from US Medicare beneficiaries between 2006–2008 showed increased all-cause readmission at 1 year.

The data on the effect of AF on HF exacerbation over the short term is lacking. In 2014, Medicare and Medicaid shifted from fee-for-service to value-based reimbursement, leading to the increased focus on preventing 30-day readmissions. Currently, there is limited information on the predictors of these short-term outcomes and the utilization of resources in patients with HF and AF. This study, aimed to identify the 30-day readmission rate, causes, and impact on healthcare in HF exacerbation with a history of AF.

METHODS

Data source

Nationwide Readmissions Database (NRD) year 2018 was utilized for retrospective analysis. NRD can be obtained from the Healthcare Cost and Utilization Project, which is sponsored by Agency for Healthcare Research and Quality. Unweighted 2018 NRD contains approximately 18 million discharges for that year, while weighted sample estimates around 35 million discharges in the US. NRD draws its sample from 28 states, which represent 59.7% of the total US population and 58.7% of all US hospitalizations.

Study population

Patients with age ≥18 years and non-elective admission with a principal diagnosis of acute HF or acute hypoxic respiratory failure with a secondary diagnosis of HF. All patients included in the study had a secondary diagnosis of AF. December month admissions were excluded as data regarding 30-day readmission cannot be calculated. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10 CM) codes were utilized to identify the patient sample.

Variable selection

Variables included in the study were divided into patient level, illness severity, and hospital level:

a. Patient level: Age, sex, median household income in the zip code, insurance status, Charlson comorbidity score
b. The severity of illness: Mechanical ventilation, cardiogenic shock, length of stay, rehabilitation transfer

c. Hospital level: Hospital location, teaching status, bed size

**Study outcomes**

The primary outcome was all-cause 30-day readmission, and any non-traumatic admission within 30 days of discharge after index admission was considered readmission. Secondary outcomes were in-hospital mortality, 30-day mortality following index admissions, top 5 principal reasons for readmissions, total length of stay and resource utilization associated with readmissions, independent predictors of readmission.

**Statistical analysis**

All statistical analysis was performed using the Stata 17.0 version (StataCorp LLC, College Station, TX, USA). Categorical variables were compared using the \( \chi^2 \) test, and linear regression was used for continuous variables. A 2-tailed p value of \( \leq 0.05 \) was considered statistically significant. All p values of \( \leq 0.2 \) on univariate Cox regression were used to build a multivariate Cox regression model to identify independent predictors.

**RESULTS**

**Patient characteristics**

A total of 48,250 patients were included in the study after excluding patients as shown in Figure 1. Patient and hospital level characteristics are shown in Table 1. Females comprised 47.74%, with a mean age of 77.8 (standard deviation, 12.1). A total of 80.77% of the population was of age \( \geq 65 \) years. Majority of patients had Charlson comorbidity score of \( \geq 3 \) and Medicare insurance. Half of the patients were treated in large hospitals.

![Inclusion and exclusion criteria diagram](https://doi.org/10.36628/ijhf.2022.0002)

**Figure 1.** Inclusion and exclusion criteria.

CHF = congestive heart failure; AF = atrial fibrillation; HFrEF = heart failure with reduced ejection fraction; HFpEF = heart failure preserved ejection fraction; EF = ejection fraction.
Thirty-day all cause readmission

Of 48,250 patients with congestive heart failure (CHF) and AF, 44,736 were discharged alive, of which 7,469 (16.7%) were readmitted in 30 days. Of 64,362 CHF patients without AF, 61,104 were discharged alive, of which 10,012 (16.38%) were readmitted in 30 days.

In-hospital mortality rate for index admission vs. readmission and 30-day mortality rate following index admission

A total of 3,514 (7.28%) died during the index hospitalization, and additional 501 patients died within 30 days of discharge. The mortality rate during readmission was higher when compared to index admission (8.12% vs. 7.28%, p=0.05). Comparison between index and readmission is show in Table 2. Further subgroup analysis showed readmission rate was 16.51% and 16.7% respectively in HFpEF and HF with reduced ejection fraction (HFrEF).

Table 3 represents the information on mortality, mechanical ventilation, cardiogenic shock, length of stay, and total charges of both the groups.

Most common all cause 30-day readmission

The most common reason for readmission was HF. Table 4 shows the five most common reasons for readmissions. Four out of 5 reasons for readmissions were due to HF.

Table 1. Index hospitalization patient characteristics with CHF and AF (n=48,250)

| Variable                          | Value            |
|-----------------------------------|------------------|
| Age (years)                       | Value            |
| 18–44                             | 1.86%            |
| 45–64                             | 17.35%           |
| 65–84                             | 51.33%           |
| ≥85                               | 29.64%           |
| Mean age (years)                  |                 |
| Female                            | 77.8±12.1        |
| Male                              | 73.3±13.4        |
| Sex (female)                      |                 |
| Median income in patients zip code ($) |                |
| <45,999                           | 25.76%           |
| 46,000–58,999                     | 30.26%           |
| 59,000–78,999                     | 24.96%           |
| ≥79,000                           | 18.99%           |
| Insurance                         |                 |
| Medicare                          | 82.12%           |
| Medicaid                          | 6.62%            |
| Private                           | 9.83%            |
| Uninsured                         | 1.41%            |
| Charlson comorbidity score        |                 |
| ≤2                                | 17.36%           |
| >3                                | 82.64%           |
| Hospital location                 |                 |
| Large metropolitan area           | 49.63%           |
| Small metropolitan area           | 37.1%            |
| Micropolitan area                 | 9.7%             |
| Not metropolitan or micropolitan area | 3.55%       |
| Teaching hospital                 | 64.47%           |
| Hospital bed size                 |                 |
| Small                             | 21.42%           |
| Medium                            | 28.09%           |
| Large                             | 50.47%           |
| Discharge to rehabilitation       | 0.87%            |

Values are presented as frequency (%) or mean±standard deviation.

CHF = congestive heart failure; AF = atrial fibrillation.
Resource utilization due to readmissions

The mean length of stay (LOS) for readmitted patients was 6.1 days when compared to index admission 6.4 days (p<0.01). Mean hospitalization charges in readmission vs. index admission were $61,693 vs. $65,741 (p=0.01). Comparison between index and readmission is show in Table 2. Total LOS incurred due to readmission was 45,706 days, with resulting total hospitalization charges of $461 million.

Independent predictors of readmission

Variable selection, multivariate cox regression model building is described in the methods section. Independent predictors for 30-day readmission were higher Charlson comorbidity score, lower median income in patients zip code, Medicare, and Medicaid insurance. Predictors associated with decreased 30-day readmission were age, private insurance, and high median income in patient’s zip codes. The rest of the variables were not linked to readmission, as shown in Table 5.
DISCUSSION

Our study has several important findings. Firstly, among patients admitted with HF exacerbation with AF, the all-cause readmission rate was 16.7% within the first 30 days of discharge from index hospitalization, and the leading cause of readmission was HF. Second, low socioeconomic status, Charlson comorbidity score, and lower median income, Medicare and Medicaid insurance were predictors for increased 30-day readmission. Third, the mortality rate during readmission was higher when compared to index admission (8.12% vs. 7.28%, p=0.05).

The 30-day readmission rate in the US is significantly higher at 16.7% compared to 9.9% from a similar population-based study in Australia. However, this is consistent with rates of HF readmission rate in the US, which was at 18.2% based on the national readmission database. Our study showed a similar rate of readmission in patients with HF with underlying AF. The data on the effect of AF on HF readmission is variable. A metaanalysis by Saito et al. revealed that having AF did not increase the risk of HF short-term readmission. Similar results were found in smaller studies in the US population, the Japanese population, and the Spanish population. Ahmed et al. showed similar findings in patients older than 65 years using Medicare data, that AF did not increase the 30 days readmission.

Having AF by itself did not increase the short-term readmission rate for HF. This might be due to advances in the management of AF in terms of ablation techniques, an
increase in the use of antiarrhythmics, novel oral anticoagulants, improvements in cardiac resynchronization therapy, and permanent pacemakers. Patients with both HF and AF are likely to have well-established outpatient care, given the complexity of management which might help prevent short-term readmissions.

In contrast to our results, Eapen et al. showed a modest increase in the 30-day readmission rate with increased hazards of 1.09 using Medicare claims data. However, a larger study sample and an all-payer source database are some of the unique features of our study. The most common cause of readmission remains HF exacerbation, similar to previous studies.

Like prior evidence in HF, our study revealed low socioeconomic status, Charlson comorbidity score, and lower median income, Medicare and Medicaid insurance were predictors for increased 30-day readmission. Around 90% of patients included in the study either had Medicare or Medicaid, and they had a high chance of readmission (29% and 47%) compared to patients with private insurance. A likely explanation might be the lack of Medicare part B and D coverage, which provides outpatient services. At the same time, very sick patients with low socioeconomic status and no insurance are likely to apply for Medicaid and have poor access to health care. These findings stress the importance of policies specifically geared towards patients of low socioeconomic status and hospitals taking care of these populations. We did not find age and gender predictive of readmission rates consistent with previous evidence.

Although the rates of cardiogenic shock and mechanical ventilation were significantly higher with index admission, the mortality rate was slightly higher in readmitted patients (8.12% vs. 7.28%, p=0.05). The underlying severity of HF and ejection fraction might drive this, and although rates were adjusted with the Charlson comorbidity index, HF AF shares similar risk factors, which increases the chance of unmeasured confounders. Nevertheless, these findings emphasize the importance of preventing readmission. Length of stay and hospitalization charges are comparable to index admission (6.1 vs. 6.4 days, p<0.001) ($61,693 vs. $65,741, p=0.01). Total preventable days of hospitalization were 45,706 for 2018, which translates to a $461 million financial burden.

Subgroup analysis showed that the mortality rate was higher in HFpEF (6.47% vs. 8.88%), while in HFrEF, mortality did not differ. The difference in mortality in HFpEF is likely due to unmeasured confounders such as degree of kidney dysfunction or sepsis, which were among the top 3 causes of readmission. Further studies are warranted if medications with mortality benefit or ablation for AF had an impact on mortality during readmission in patients with HFrEF and AF.

As with any cross-sectional study, we cannot establish causality but only associations. Our study is based on a database based on ICD-10 CM coding, which can include possible coding errors/risk factors or diagnoses not entered into the database. We did not distinguish between different types of AF and lacked information on race, type of antiarrhythmics drugs used, laboratory data, imaging findings, baseline vital signs and if has had any outpatient ablation procedures for AF. We could not evaluate social barriers for discharge or readmission, outpatient resource accessibility, and medication compliance. NRD does not record out-of-state readmissions.

In conclusion, the 30-day readmission rate was 16.7% in HF patients with concurrent AF. Readmitted patients had a higher mortality rate when compared to the index admission. Low
socioeconomic status, comorbidities, Medicare and Medicaid insurance, are independent predictors for 30-day readmission. Financial burden incurred from readmission was $461 million for the year 2018. Future studies directed with interventions to prevents readmissions are warranted.

REFERENCES

1. Santhanakrishnan R, Wang N, Larson MG, et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016;133:484-92. 
   PUBMED | CROSSREF
2. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020;141:e139-596. 
   PUBMED | CROSSREF
3. Benjamin EJ, Muntnner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56-528. 
   PUBMED | CROSSREF
4. Santema BT, Kloosterman M, Van Gelder IC, et al. Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. Eur Heart J 2018;39:3867-75. 
   PUBMED | CROSSREF
5. Son MK, Park JJ, Lim NK, Kim WH, Choi DJ. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. Heart 2020;106:1160-8. 
   PUBMED | CROSSREF
6. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017;5:565-74. 
   PUBMED | CROSSREF
7. Zafrir B, Lund LH, Laroché C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 2018;39:4277-84. 
   PUBMED | CROSSREF
8. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in Heart Failure—Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999;5:276-82. 
   PUBMED | CROSSREF
9. Khazanie P, Liang L, Qualls LG, et al. Outcomes of Medicare beneficiaries with heart failure and atrial fibrillation. JACC Heart Fail 2014;2:41-8. 
   PUBMED | CROSSREF
10. Introduction to the HCUP Nationwide Readmissions Database (NRD) 2010–2018. Santa Barbara: HCUP Central Distributor; 2021 [cited 2021 October 12]. Available from: https://www.hcup-us.ahrq.gov/db/nation/nrd/Introduction_NRD_2010-2018.pdf.
   PUBMED | CROSSREF
11. Wang N, Hales S, Toft G. 15-Year trends in patients hospitalised with heart failure and enrolled in an Australian Heart Failure Management Program. Heart Lung Circ 2019;28:1646-54. 
   PUBMED | CROSSREF
12. Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail 2021;14:e008335. 
   PUBMED | CROSSREF
13. Saito M, Negishi K, Marwick TH. Meta-analysis of risks for short-term readmission in patients with heart failure. Am J Cardiol 2016;117:626-32. 
   PUBMED | CROSSREF
14. Patel KB, Vaduganathan M, Rikhi A, et al. History of atrial fibrillation and trajectory of decongestion in acute heart failure. JACC Heart Fail 2019;7:47-55. 
   PUBMED | CROSSREF
15. Murakami M, Niwano S, Koitabashi T, et al. Evaluation of the impact of atrial fibrillation on rehospitalization events in heart failure patients in recent years. J Cardiol 2012;60:36-41. 
   PUBMED | CROSSREF
16. Hamaguchi S, Yokoshiki H, Kinugawa S, et al. Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009;73:2084-90.

17. Franco J, Formiga F, Cepepa J, et al. Influence of atrial fibrillation on the mortality of patients with heart failure with preserved ejection fraction. Med Clin (Barc) 2018;150:376-82.

18. Ahmed A, Thornton P, Perry GI, Allman RM, DeLong JF. Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure. Eur J Heart Fail 2004;6:421-6.

19. Vecchio N, Ripa L, Oroco A, et al. Atrial fibrillation in heart failure patients with preserved or reduced ejection fraction. prognostic significance of rhythm control strategy with catheter ablation. J Atr Fibrillation 2019;11:2128.

20. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012;125:381-9.

21. Eapen ZI, Greiner MA, Fonarow GC, et al. Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. Am Heart J 2014;167:369-375.e2.

22. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360:1418-28.

23. Howie-Esquivel J, Dracup K. Effect of gender, ethnicity, pulmonary disease, and symptom stability on rehospitalization in patients with heart failure. Am J Cardiol 2007;100:1139-44.

24. Wideqvist M, Cui X, Magnusson C, Schaufelberger M, Fu M. Hospital readmissions of patients with heart failure from real world: timing and associated risk factors. ESC Heart Fail 2021;8:1388-97.

25. Carlson B, Hoyt H, Gillespie K, Kunath J, Lewis D, Bratzke LC. Predictors of heart failure readmission in a high-risk primarily Hispanic population in a rural setting. J Cardiovasc Nurs 2019;34:267-74.

26. C L, H C, S R, et al. Trends in 30-day readmissions following hospitalisation for heart failure by sex, socioeconomic status and ethnicity. EClinicalMedicine 2021;38:101008.

27. Centers for Medicare & Medicaid Services. Hospital Readmissions Reduction Program (HRRP). Baltimore: Centers for Medicare & Medicaid Services; 2021 [cited 2021 October 12]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.

28. Hoang-Kim A, Parpia C, Freitas C, et al. Readmission rates following heart failure: a scoping review of sex and gender based considerations. BMC Cardiovasc Disord 2020;20:223.

29. Gevaert SA, de Bacquer D, Willems AM, et al. Gender differences in the management and outcome of atrial fibrillation complicating acute heart failure. J Card Fail 2014;20:431-7.